ArticleThe Journal of pathology2012

Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.

Fiona Furlong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.